The Alliance for Biosecurity is a coalition of biopharmaceutical companies and laboratory/academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security. The Alliance advocates for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures.
The Alliance has been highly influential on key issues relevant to biosecurity and development of MCMs, including:
Advocated to preserve the BioShield Special Reserve Fund (SRF) – critical source of funding for MCM development and procurement – and successfully advocated against at least 3 proposed Congressional “raids” (up to $2 billion) of the SRF.
Successfully advocated for five-year reauthorization of BARDA and SRF in the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Served as trusted resource for Congressional staff working to better integrate FDA into the MCM development process; secured strong legislative changes in PAHPRA.
Constructively engaged with FDA on critical policy/regulatory issues related to development of MCMs, including animal models. During 2012, the Alliance was invited by FDA to (i) participate in a “hot topics” educational briefing for FDA reviewers and other professionals, and (ii) provide perspectives on GLP issues when conducting animal model studies in BSL-3 and BSL-4 Labs.
Convened an informal coalition of stakeholders (including public health and national defense organizations) committed to the long term success of the US government’s biodefense and public health preparedness enterprise to strengthen education and outreach efforts.
Senior Vice President,
Global Government Affairs, Emergent BioSolutions
"The Alliance for Biosecurity is a strong, focused, respected, and influential organization. By leveraging our collective knowledge and expertise, the Alliance is committed to building and strengthening the partnerships between government and the biopharmaceutical industry and to help identify and provide solutions to the threats facing our nation. The Alliance will continue to seek opportunities to influence policy while understanding the political realities."
Senior Vice President, Commercial Operations,
"Public-private partnerships for the development and availability of MCMs are a core element of global health security. The Alliance for Biosecurity is vital to ensuring that these partnerships are sustained and remain strong to support this essential mission.
MCMs provided by the companies of the Alliance contribute significantly to preparedness and response capabilities against a variety of naturally occurring threats such as pandemic influenza and intentional chemical, biological, radiological and nuclear threats. For more than a decade, Alliance member companies have successfully advocated for public policies and funding to strengthen the public-private partnership that ensures the availability of needed medical countermeasures to respond to serious threats such as Ebola, Anthrax, Smallpox and Pandemic Influenza. Speaking together as a single industry voice increases the opportunity for our message to be heard, understood and acted upon."